pioglitazone has been researched along with Multiple Sclerosis in 6 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with metformin and pioglitazone has beneficial anti-inflammatory effects in patients with MS and MetS and should be further explored." | 5.43 | Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. ( Correale, J; Farez, MF; Negrotto, L, 2016) |
| "Treatment with metformin and pioglitazone has beneficial anti-inflammatory effects in patients with MS and MetS and should be further explored." | 1.43 | Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. ( Correale, J; Farez, MF; Negrotto, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Negrotto, L | 1 |
| Farez, MF | 1 |
| Correale, J | 1 |
| Feinstein, DL | 2 |
| Galea, E | 1 |
| Gavrilyuk, V | 1 |
| Brosnan, CF | 1 |
| Whitacre, CC | 1 |
| Dumitrescu-Ozimek, L | 1 |
| Landreth, GE | 1 |
| Pershadsingh, HA | 1 |
| Weinberg, G | 1 |
| Heneka, MT | 3 |
| Schmidt, S | 1 |
| Moric, E | 1 |
| Schmidt, M | 2 |
| Sastre, M | 2 |
| Klotz, L | 1 |
| Giese, T | 1 |
| Knolle, P | 1 |
| Klockgether, T | 1 |
| Peiris, M | 1 |
| Monteith, GR | 1 |
| Roberts-Thomson, SJ | 1 |
| Cabot, PJ | 1 |
| Niino, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability[NCT00242177] | Phase 1 | 30 participants | Interventional | 2003-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pioglitazone and Multiple Sclerosis
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.
Topics: Animals; Anti-Inflammatory Agents; Encephalomyelitis, Autoimmune, Experimental; Humans; Multiple Scl | 2007 |
5 other studies available for pioglitazone and Multiple Sclerosis
| Article | Year |
|---|---|
Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis.
Topics: Adipokines; Anti-Inflammatory Agents; Brain; Cohort Studies; Cytokines; Disability Evaluation; Dose- | 2016 |
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.
Topics: Animals; Cerebellum; Cerebral Cortex; DNA-Binding Proteins; Encephalomyelitis, Autoimmune, Experimen | 2002 |
Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Anti-Inflammatory Agents; Case-Control Studies; Cell Divi | 2004 |
Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Diabetes Mellitus, Type 2; DNA; Fem | 2005 |
A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies.
Topics: Adjuvants, Immunologic; Animals; Central Nervous System; Chemotaxis, Leukocyte; Disability Evaluatio | 2007 |